Incyte has reported final 24-week data from the Phase III TRuE-AD4 study. The results show sustained efficacy along with a consistent safety profile for Opzelura (ruxolitinib) cream in adults with ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
TransCelerate BioPharma has released a summary report from a joint tabletop exercise conducted with the FDA's Center for Drug ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results